부산대학교 도서관

Simple Summary: Lung cancer (LC) is one of the most common and serious types of cancer. Unfortunately, it is not easy to detect in the early stages of the disease due to the absence of symptoms. Many patients have late-stage LC when they are diagnosed, and this is associated with limited treatment options and poor survival rates. To try to improve this, we have assessed which proteins in LC patients are recognised by the immune response and could be used to screen at-risk patients for LC before symptoms appear. We have shown that panels of blood and sputum biomarkers may offer the most effective way to improve early LC detection. Lung cancer (LC) is one of the leading causes of cancer-related deaths. Pulmonary nodules are one of the risk factors, and their discovery rate has been increasing due to enhanced performance of chest CT scans, but more than 90% are non-malignant, causing unnecessary stress to patients and costs to healthcare providers. Early diagnosis of LC is associated with a 5-year survival rate of up to 75% following surgical resection, but LC is often diagnosed late due to a lack of symptoms and poor 5-year survival rates as low as 10%. The cost of LC diagnosis is high, with 40% of it associated with benign lesions, which are difficult to differentiate from malignant lesions. Tumour-associated antigens (TAAs) may provide one way in which LC could be diagnosed early using minimally-invasive techniques, under their association with immune responses and specificity for disease. Here we discuss the potential of cancer-testis antigens (CTAs) to act as non-invasive biomarkers for the early detection of non-small cell lung cancer. [ABSTRACT FROM AUTHOR]